Aixtron

Phase A — Understand the business

Company Overview

AIXTRON makes the deposition equipment that grows the crystalline layers of compound (non-silicon) semiconductors — principally MOCVD (metal-organic chemical vapor deposition) and CVD systems. It does not make chips; it makes the machines chipmakers use to epitaxially grow gallium-nitride (GaN), silicon-carbide (SiC), gallium-arsenide (GaAs), indium-phosphide (InP) and related III-V materials onto wafers. Those materials become power electronics, RF, LEDs/micro-LEDs, lasers and photonic components. In semicap terms AIXTRON is the "ASML of compound semiconductors" for the epitaxy step — a narrow, deep, tools-and-consumables franchise, not a broad process-equipment vendor.

Business model. Sell a high-ASP capital tool (a G10 platform system runs into the multiple €-millions), then earn a long recurring tail on spares, upgrades, and service as the installed base grows. Revenue is lumpy and shipment-timed — a single quarter can swing ±50% on when big multi-tool orders ship (Q1/2026 rev €59.4m vs Q4/2024 €226.9m). The order book, not the quarterly P&L, is the real health signal.

Three end-market segments (FY2025 equipment revenue mix):

• SiC + GaN power electronics — 57%. Flagship: the G10-SiC platform (100th system delivered <3 years after launch; large China volume orders H1/2025). End use: EVEnterprise valueWhat it would cost to buy the whole company: its market value plus its debt, minus the cash you would get with it. Often very different from market cap. traction inverters, industrial power, 800V data-center power.
• Optoelectronics — 23% and rising fast. Flagship: G10-AsP for InP/GaAs lasers and detectors — the AI-optics engine (800G/1.6T optical modules, co-packaged optics).
• LED incl. micro-LED — 15%, the weakest leg.

Customers (Lens 2 detail): compound-semi foundries and IDMs — Lumentum, Nokia, SMART Photonics (named opto buyers 2026), Chinese SiC makers, LED/micro-LED and RF houses. Contract structure is book-and-ship capital orders — not take-or-pay, not subscription; concentration risk is by end-market cycle and by geography (China) rather than by a single named customer.

Supply Chain

Map: upstream inputs → AIXTRON (integrator) → epi-wafer/chip maker → device OEM → end system.

• Upstream into AIXTRON: precision-machined stainless/graphite reactor chambers and susceptors; showerhead/injector assemblies (AIXTRON's core IP); mass-flow controllers and gas-delivery (e.g. MKS/Brooks-class suppliers ); RF/heating and motion-control subsystems; automation/robotics for cassette-to-cassette handling; and the metal-organic precursor chemistry ecosystem (TMGa, TMAl, arsine/phosphine handling) which AIXTRON's tools must safely process — precursor supply (Dow/SAFC-class) is an adjacent chokepoint for AIXTRON's customers, not AIXTRON itself.
• AIXTRON's own step: designs and integrates the reactor + injector + control software; the planetary reactor / Close Coupled Showerhead geometry and thermal uniformity is the crown-jewel process IP.
• Downstream customers (the buyers): SiC/GaN power foundries (China domestic makers, Western IDMs), InP/photonics houses — Lumentum, Nokia (opto), SMART Photonics, LED/micro-LED fabs, RF/GaAs makers → whose chips flow to EV OEMs, hyperscaler optical-module vendors (→ NVIDIA/Broadcom AI networks), and consumer-display makers.

Chokepoints / single-source dependencies: (1) AIXTRON is itself a near-duopoly chokepoint in high-end MOCVD — for AI-optics InP epitaxy at scale, the practical choice is AIXTRON (G10-AsP) or Veeco. (2) China gallium/germanium export controls and US-led equipment export controls are a two-way chokepoint: China restricts Ga/Ge feedstock (hurts customers), the West restricts advanced-tool exports to China (hurts AIXTRON's largest growth market). (3) Precursor gas handling and 300mm GaN process readiness are capability chokepoints AIXTRON is spending to own (Herzogenrath innovation center, first 300mm GaN).

Competitive Advantages (Moats)

• Process IP + installed base (the real moat). Two-plus decades of epitaxy know-how — reactor geometry, thermal uniformity, defect density — encoded in the G10 platforms. Switching a qualified epi recipe to a rival tool is expensive and slow (re-qualification, yield risk), giving high switching costs once a fab standardizes on AIXTRON.
• Duopoly structure. AIXTRON + Veeco control an estimated ~55-65% of global MOCVD revenue in 2025; historically AIXTRON ~58% share (2020). In the specific InP-for-AI-optics niche AIXTRON's G10-AsP is positioned as the volume benchmark.
• Technology lead at the frontier. First 300mm GaN wafer processing; G10-AsP repeat orders from blue-chip opto names — early-mover in the exact node the AI build-out needs.
• Bargaining power — asymmetric. Strong over most suppliers (commoditized subsystems). Moderate over customers: in a boom (opto now) AIXTRON has pricing power and long lead times; in a bust (SiC now) customers hold utilization/capex hostage and orders evaporate. The moat protects share and margin-through-cycle, not quarter-to-quarter demand.
• Moat erosion vector: AMEC (Advanced Micro-Fabrication, China) — state-backed, ~16% share (2020) and rising under China's domestic-procurement preference. In China SiC/LED, AMEC is a structural share-taker; AIXTRON's China moat is the weakest link.

Segments

No our figures on disk — all. FY2025 equipment-revenue mix and direction:

The whole story in one line: the demand engine is rotating out of power (57% of the base) into opto (the growth) — but opto was only ~23% of FY2025, so the mix shift is early. Geography: China is the swing region for SiC (stabilizer in 2025, hostage to export controls in 2026); US/EU benefit from CHIPS-adjacent SiC/GaN investment. Geographic revenue split not disclosed at segment level in sourced material → n/a for exact geo-EBIT.

---

Phase B — Measure performance

Earnings Result — Q1/2026 (the trough print) + FY2025 actuals

Q1/2026 (reported ~30 Apr 2026) — a deliberate revenue trough with a violent margin hit, paired with a booking surge:

• Revenue €59.4m, -47% YoY (Q1/2025 €112.5m) — within the €65m ±€10m guide (low end).
• Gross profit ~€11m; gross margin ~18% (Q1/2025: 30%).
• EBIT €-22m; EBIT margin ~-38% (Q1/2025: +3%). An operating loss.
• Order intake €171.4m, +30% YoY — ~70% optoelectronics.
• Equipment order backlog €359.1m, +17% YoY (€307.9m) and up from €257.8m at end-2025.
• SiC = 14% of equipment revenue; GaN = 3% — both at cyclical lows.
• Q2/2026 guided to ~€110m ±€10m — revenue nearly doubling QoQ as big system shipments begin.

The market reaction / what was priced in: shares fell ~9% on the weak Q1/FY guide back in early 2025; the Q1/2026 order beat + FY guidance raise is what re-rated the stock toward €60. The tape now trades the order book and the opto narrative, and looks through the printed loss — classic early-cycle semicap behavior.

FY2025 actuals:

• Revenue €556.6m, -12.1% (FY2024 €633.2m).
• Net profit €85m, -20%. → EPS ≈ €0.75 [share count: eulerpool, 2026].
• Gross margin 40% (-1pp). Operating cash flow €208m (+€180m). Cash €225m (up from €65m). Dividend €0.15 (cut from €0.40 the prior year).
• FY2025 order intake €544m; end-2025 backlog €258m (-11% YoY).

Balance-sheet flags: pristine — equity ratio ~85%, D/E ~0.01, net cash, current ratio ~5.6. The FY2025 cash build (€65m→€225m) came from working-capital release as revenue fell — a good sign of discipline, but partly a cyclical inventory drawdown that reverses when shipments ramp (Q2/2026+). Watch inventory rebuild against the €359m backlog.

FY2026 guidance — RAISED (with Q1 prelims, Apr 2026):

• Revenue ~€560m (±€30m), up from €520m.
• Gross margin ~42% (from 41-42%). EBIT margin 17-20% (from 16-19%).

Earnings Calls (sentiment trend)

No transcripts/ on disk —, from call highlights/IR speeches across FY2024→Q1/2026:

• 2024 calls: defensive — SiC glut, EV slowdown, micro-LED delays, "unfavorable product mix," dividend cut. Tone: managing a downturn.
• Q2-Q3/2025 calls: the pivot — "clear improvement in market dynamics," optoelectronics/AI photonics repeatedly named as the new driver; SiC framed as China-stabilized, Western-soft. First appearance of "robust pipeline well beyond 2026."
• Q1/2026 call (30 Apr 2026, Grawert + new CFO Danninger): most bullish in years on orders despite the worst margin print — "high multi-tool order activity," opto ~70% of bookings, guidance raised, GaN recovery "later in 2026," SiC recovery "H2/2026 or early 2027."

Phrases that entered the vocabulary: "AI-era photonics," "chip-to-chip / rack-to-rack / datacenter-to-datacenter," "G10-AsP benchmark," "300mm GaN," "multi-tool orders." Phrases they stopped leaning on: micro-LED (the 2021-2022 hope), and the confident SiC/EV-supercycle framing of 2023. The tone shift is from defending a cyclical trough to selling a secular opto growth story — genuine, but note management is now incentivized to keep the opto narrative loud.

Comps

Peer set: high-end deposition/epitaxy + broad semicap. Multiples are with source/date or n/a. AIXTRON's own multiples are off sourced price + FY2025 actuals.

Read: on EV/Sales ~11x AIXTRON trades at ~2x Veeco (5.4x) and near ASML-monopoly territory — extraordinary for a €556m-revenue, cyclically-troughed name. The ~74x trailing P/E is a trough-earnings artifact (net profit fell to €85m; Q1/2026 was a loss), so P/E overstates richness — but even normalizing to a mid-cycle ~€130-150m net income implies ~42-48x, still a full premium to AMAT (26x) and Veeco (23x). The market is paying an ASML-like multiple for the AI-optics call option. That is the entire bull-bear crux.

Stock-Price Catalysts (moves >5%, last ~2 years — )

• 2024 H1-H2 — down ~40% cumulatively: SiC/GaN glut, EV downturn, telecom weakness, micro-LED delays; a July 2024 FY2024 guidance framing and repeated soft prints.
• Feb 2025 — −9% on weak Q1/FY2025 guidance + margin concerns + dividend cut €0.40→€0.15.
• Recurring −5%+ on China export-control headlines (US pressing Germany/NL/JP/KR to restrict China tool access) — AIXA fell to ~€27 on one such scare.
• Late 2025 — sharp rally on the opto pivot + the Kerrisdale long thesis (Nov 2025) publicizing a 271-322% upside case; "record stock" / "300% rally" references.
• 2026 — up on order beats (Q1 order intake +30%, FY guidance raise), reaching €60.16 on 22 Jun 2026.

Pattern — what actually moves AIXA: (1) order intake / backlog far more than reported revenue (it's an early-cycle book-to-billBook-to-billNew orders divided by orders filled. Above 1 means the backlog is growing; below 1 means the company is working through it faster than it is replacing it. stock); (2) guidance direction (cuts crush, raises re-rate); (3) China export-control headlines (binary geopolitical risk); (4) the AI-optics narrative (now the dominant driver). The market reacts to forward booking signals and the opto story, and looks through trough margins.

---

Phase C — Judge people & books

Management

• CEO Dr. Felix Grawert — on the executive board since 2017, CEO since 1 Apr 2021; contract extended early (Sept 2024) to mid-Aug 2030 — a strong supervisory-board endorsement. Track record: "more than doubled total sales since taking office"; drove the G10 platform generation and the strategic pivot into AI-optics — the single best call management has made. Physicist/operator archetype (ex-Bosch), not founder.
• CFO Dr. Christian Danninger — presenting Q1/2026 (Apr 2026); a recent CFO transition — new finance leadership through the trough.
• Supervisory board refresh (May 2025): Alexander Everke (ex-CEO ams-OSRAM) elected Chairman; Ingo Bank (CFO, City Football Group) added — credible semiconductor + finance oversight.
• Capital allocation: conservative and shareholder-cautious. Dividend cut €0.40→€0.15 (FY2024) to fund investment — defensible in a downturn but a signal the board prioritizes the balance sheet over payout. ~€100m Herzogenrath innovation center (300mm GaN) — the right offensive R&D bet. R&D €91.4m (2024) vs €87.7m (2023), sustained through the trough. 2026 AGM granted a buyback-and-cancel authorization + authorized capital — optionality, not yet deployed.
• Skin in the game: insider ownership not sourced (n/a; no our figures). AIXTRON is widely held, no controlling shareholder — a professional-manager governance profile.
• Red flags: none material on governance. The soft flag is narrative management — the team is now heavily talking the AI-optics book while the reported P&L is at a loss; watch for order-timing optics (pull-forwards) flattering the backlog headline.

Forensic Red Flags

No filings on disk; income-statement/balance-sheet review is off reported figures. AIXTRON reports under IFRS (German HGB/IFRS), audited — not SEC-registered.

• Revenue recognition: capital-equipment rev is shipment/acceptance-timed → the enormous quarterly swings (€59m→~€110m guided) are legitimate lumpiness, but they make any single quarter a poor read and create room for timing management across period-ends. Watch revenue vs. order-backlog conversion cadence.
• Cash flow vs. earnings: FY2025 operating cash flow €208m >> net income €85m — cash ahead of earnings, driven by working-capital release as revenue fell (inventory/receivables drawdown). Healthy today, but it reverses on the ramp — Q2/2026+ shipments will consume cash into inventory/receivables. A cash-flow decline in 2026 would be mechanical, not a red flag; mis-reading it as deterioration is the trap.
• Receivables/inventory: working capital down >€76m since end-2025 — consistent with the trough. The risk is on the rebuild: if backlog ships and receivables balloon against China customers under export-control stress, collection risk rises.
• SBC / non-GAAP: not sourced in detail (n/a); AIXTRON's compensation SBC is modest by semicap standards and it reports clean EBIT (not a heavy adjusted-EPS storyteller).
• Goodwill/intangibles: minimal — AIXTRON grows organically, not by acquisition; low impairment risk.
• Balance sheet: 85% equity, net cash, D/E 0.01 — essentially no financial-risk flags.

Regulatory findings (required). Per regulatory/regulatory-findings.md (fetched 2026-07-01): AIXTRON has no CIK — no SEC EDGAR search possible; total_sec_findings: 0. Non-SEC web check ("Aixtron" (FTC/DOJ/FDA/EU/consent decree/fine/penalty) enforcement): no material enforcement action found. The material regulatory exposure is export-control, not misconduct — AIXTRON operates under German/EU/US dual-use export-control regimes; recurring headline risk that China SiC/GaN/opto tool sales get restricted (US pressing allies). Historical note: AIXTRON's 2016 attempted acquisition by China's Fujian Grand Chip was blocked on US/German national-security grounds — the definitional precedent that AIXTRON tools are geopolitically sensitive. No litigation/AAER/fraud findings. Verified via absence of SEC CIK (no LR/AAER possible), web enforcement search, and public disclosure as of 2026-07-01; 10-K Item 3 n/a (foreign filer, no EDGAR).

---

Phase D — Project & stress-test

Forward Projection (EPS, FY2026-FY2028) —, web-grounded inputs

Base off FY2025 actuals (rev €556.6m, net €85m, ~112.6m shares, EPS ≈€0.75) and management's raised FY2026 guide (rev ~€560m, EBIT margin 17-20%). Net margin ≈ EBIT margin × ~0.80 (tax) + small net-cash interest income. Share count roughly flat (buyback authorized but undeployed).

FY2026 (base): rev ~€560m; EBIT margin ~18.5% (mid) → EBIT ~€104m; net ~€88m → EPS ≈ €0.78. H2-weighted: Q1 was a loss, Q2 ~€110m, back half carries the year via the €359m backlog.

FY2027 (base): opto ramp continues + GaN utilization recovery (late-2026 into 2027) + early SiC recovery. Rev ~€680-720m; margin recovers to ~21-22% on volume leverage → net ~€120-130m → EPS ≈ €1.05-1.15.

• Bull FY2027: opto compounds + China SiC re-accelerates + micro-LED optionality → rev ~€800m+, EPS ~€1.40+ (approaches the Kerrisdale trajectory).
• Bear FY2027: opto orders prove pull-forward / lumpy, China export controls tighten, SiC stays glutted → rev ~€560-600m (flat), EPS ~€0.75-0.85.

FY2028 (base): rev ~€800m, mid-cycle margin ~23% → EPS ≈ €1.35-1.45. Kerrisdale's bull frames €1.06bn 2028 revenue vs consensus ~€693m — my base sits between the two, closer to consensus.

Valuation check: at €60.16, the base FY2028 EPS ~€1.40 implies a forward P/E ~43x on a two-years-out number — the price already discounts a successful multi-year opto ramp. our model create skipped (watchlist loop rule — no committed base case logged).

Bull vs Bear

Bull case. AIXTRON is the arms dealer for two secular build-outs at once — AI-optics (InP lasers/detectors for 800G→1.6T, where G10-AsP is the volume benchmark and orders are landing at Lumentum/Nokia/SMART) and, eventually, the SiC/GaN power recovery (EV + 800V data-center power). It sits in a duopoly (~55-65% MOCVD share) with deep switching costs, a fortress balance sheet (85% equity, net cash), first-mover 300mm GaN, and a management team that called the opto pivot early and raised guidance into a trough. Order intake +30%, backlog €359m and building, book-to-bill well above 1. If opto is a durable multi-year S-curve (Kerrisdale: €1.06bn 2028 rev, 271-322% upside), today's €6.3bn cap is early.

Bear case (permanent-impairment risks). (1) The multiple, not the business, is the risk — ~11x EV/Sales and a ~74x trough P/E price the opto boom as permanent and linear; any order air-pocket de-rates the stock 30-50% regardless of the moat. (2) China is 2-sided and structurally deteriorating — SiC/LED share bleeding to state-backed AMEC under domestic-procurement rules, and Western export controls can wall AIXTRON out of its biggest growth region overnight (the Fujian-Grand-Chip block set the precedent). (3) Opto concentration + lumpiness — the growth is a handful of optical-module customers (Lumentum et al.); AI-optics capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs. is itself a derivative of hyperscaler capex, so AIXTRON is two cycles removed from end-demand and whipsaws hard. Pre-mortem (18 months out, thesis broke): opto orders were a 2025-2026 capacity pull-forward that digests through 2027; SiC recovery slipped again; China controls tightened; revenue lands flat ~€560m, EPS ~€0.80 — and a stock priced for €1.40+ EPS halves to the low-€30s (near analysts' €23.5 low PT). Contrarian view the market is refusing to see: the opto order surge is real but the Street is extrapolating a lumpy, customer-concentrated, hyperscaler-derivative order book as if it were ASML-grade recurring demand — it is not; AIXTRON is a great business trading like a monopoly it isn't.

Devil's Advocate (short-seller)

Dismantling the bull:

• Where revenue concentrates: ~57% still SiC/GaN power — in a glut/loss (Q1/2026 EBIT -38%). The "growth" (opto) is ~23% of the base and rests on a few optical-module names whose own orders are a bet on hyperscaler optics capex. If NVIDIA/Broadcom optical-interconnect timelines slip or shift to silicon photonics that needs less InP epitaxy, AIXTRON's opto TAM shrinks at the source.
• Weaker moat than bulls think: the moat is real in the West but porous in China, the largest volume market — AMEC + Tang Optoelectronics + LPE + state procurement erode share in exactly the SiC/LED segments that are 57% of revenue. The duopoly is a Western duopoly.
• Most dangerous competitor bulls underrate: AMEC — not on today's tech, but on China policy. Every tool China buys domestically is a tool AIXTRON never sells, and export controls accelerate China's domestic substitution.
• Worst capital-allocation move: none egregious — but the dividend cut while the stock later ran 300% means holders got neither yield nor a buyback at the low; the buyback authorization arrives after the re-rating, not at €27.
• What must hold for €60: opto compounds to ~€300m+ revenue by 2028 and margins normalize to 22-23% and China doesn't get walled off and multiples stay premium. That's four things, three of them exogenous.
• -20-30% growth-disappointment scenario: if FY2027 rev lands 25% below the bull path (~€520-560m flat), the stock has no earnings support at 43x-forward and re-rates toward the €23.5-€30 analyst-low zone — a 50%+ drawdown. The single permanent-impairment scenario: China export controls + AMEC substitution jointly and permanently remove China SiC/LED, structurally shrinking the addressable base — plausible (30-40% likelihood over 3 years ) and only partially offset by opto.

Fifteen Questions for the CEO (ordered by information value)

1. Of the €171m Q1/2026 order intake, how much is net-new capacity vs. pull-forward of orders that would otherwise have landed in 2027 — and what's the true underlying book-to-bill ex-timing?
2. What share of the optoelectronics order book is concentrated in your top 3 customers, and how correlated is that demand to a single end-driver (hyperscaler 800G/1.6T optical-module capex)?
3. If silicon photonics displaces InP for a meaningful slice of AI optical interconnect, how much of the G10-AsP TAM is at risk, and on what timeline?
4. What is your realistic China revenue trajectory under the current export-control regime, and what's the downside if allied controls tighten to Netherlands/Japan levels?
5. How much SiC/LED share have you actually lost to AMEC in China over the last three years, and where does it stabilize?
6. At ~11x EV/sales the market prices durable growth — what order-book or margin evidence would you point to that this opto ramp is structural, not a 2025-2026 capacity spike?
7. Walk through the path back to a 25%+ EBIT margin: how much is volume leverage vs. mix (opto vs. power) vs. price?
8. When SiC/GaN power recovers (H2/2026-2027), what normalized margin does that segment carry now vs. the last up-cycle, given Chinese price competition?
9. Cash went €65m→€225m on working-capital release; how much reverses as the €359m backlog ships in 2026-2027, and what's your target net-cash floor?
10. With a buyback authorization now in hand, at what valuation would you actually repurchase — and why buy back near highs rather than at the 2024-2025 lows?
11. What is your 300mm GaN commercialization timeline, which customers are qualifying, and when does it move revenue?
12. What's the micro-LED optionality worth now — dead, dormant, or a real 2027-2028 driver?
13. How do you defend injector/reactor process IP against Chinese reverse-engineering and talent poaching?
14. What insider ownership do the executive and supervisory boards hold, and how is long-term comp tied to through-cycle ROIC rather than annual orders?
15. What would you have to see to conclude the opto boom has peaked, and how quickly can you flex opex given the fixed-cost, lumpy-revenue model?

---